Uniting Global Biopharma Leaders to Accelerate the Next Generation of Non-Opioid Pain Therapeutics
One year on from Vertex Pharmaceuticals' milestone JOURNAVX® approval, making history as the first new class of pain medicine in decades, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment, projected to hit $124bn by 2034. M&A headlines, including Eli Lilly's $1bn+ acquisitions of SiteOne Therapeutics and 4E Therapeutics, AbbVie's $745m licensing deal with Haisco Pharmaceutical, continue to fuel the pain innovation flywheel.
As companies race to build on the first major clinical validation of the space, attention is rapidly expanding beyond sodium channels as a ‘silver bullet’ toward neuroimmune pathways, neurotrophin biology, GLP-1 signaling, potassium channels, gene regulation, and other emerging mechanisms.
Bringing together 150+ senior leaders across pain biology, drug discovery, translational science, clinical development, medical affairs, business development, venture capital, and patient advocacy, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals, Eli Lilly, AbbVie, Grünenthal, Xenon Pharmaceuticals, Levicept, Tonix Pharma, Maxona Pharmaceuticals, 4E Therapeutics, NIH, Harvard Medical School, and leading investment firms to explore emerging mechanisms, new clinical data, trial design innovations, placebo mitigation strategies, translational models, patient-centered development approaches, and the investment trends shaping the future of pain therapeutics.
I think that interaction between academia, small startups, and Pharma is critical for advancing development of next generation treatments for pain, and these small, highly focused meetings between leaders in these 3 areas are a key way to make that happen. That is why I have come in the past to this conference series, and why I am a speaker and attendee for this meeting.
University of Texas & Co-Founder - 4E Therapeutics
This is a top pain conference to learn about progress in non-opioid analgesic R&D, discuss with industry and academic experts in pain drug development, and problem-solve key R&D hurdles to advance the field of next-generation analgesics. The conference is small for good networking, and the topics are highly relevant to drug developers. An important event for anyone in pain R&D.
Vincent Nadeau, Principal - BSQUARED Capital
Pain is arguably the most universal affliction experienced by humans. Finding effective, non-addictive solutions for pain is one of the greatest challenges the biomedical community faces. Attending this conference is an exceptional way to learn about cutting-edge developments in the space.
Roman Camarda, Principal - Novo Holdings
As an investor, this conference is a valuable opportunity to understand the latest developments in non-opioid therapeutics and hear perspectives from researchers, clinicians, and companies in the field. It also provides an excellent setting to connect with experts and emerging companies and potentially identify investment opportunities.
Jana Obajdin, Analyst, - BGV Ventures
Explore the Full Event Guide
- 30+ World Class Speakers with Cutting Edge Insights
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicated Tracks of Workshop Content Spanning Pain Biology, Target Validation, Placebo Control, Optimized Trial Design & More for the Whole Team
2027 Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into 2 tracks, spanning discovery – clinical development and access, 3 preconference day workshops and 30+ expert speakers shaping the future of pain therapeutics
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider to pain drug developers
Join Biopharma Experts
Network with pharma, biotech, VC, academia, advocacy and regulatory voices driving real-world adoption